{"@id":"https://bioecon.ru/technology/conditionally-active-nanobody-drug-conjugates/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/conditionally-active-nanobody-drug-conjugates/","json":"https://cn.bioecon.ru/api/v1/technology/conditionally-active-nanobody-drug-conjugates/index.json"},"id":"conditionally-active-nanobody-drug-conjugates","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/jiangsu-hengrui-medicine/","https://bioecon.ru/companies/daiichi-sankyo/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/isomorphic-labs/","https://bioecon.ru/companies/atomwise/","https://bioecon.ru/companies/ecowin/","https://bioecon.ru/companies/fermelanta/","https://bioecon.ru/companies/esco-aster/"]},"maturity":7,"name":"肿瘤微环境条件激活型纳米抗体偶联药物","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"微环境敏感染色筛选"},{"n":2,"title":"定点位点酶促偶联"},{"n":3,"title":"三维实体瘤组织穿透验证"},{"n":4,"title":"系统安全性与快速代谢清除"}],"summary":"经工程化改造的单域VHH纳米抗体，仅在酸性或缺氧的实体瘤微环境中特异性结合靶抗原并释放细胞毒性载荷，彻底克服传统ADC在正常组织中的脱靶毒性。","url":"/technology/conditionally-active-nanobody-drug-conjugates/","verified":"2026-11-22"}